Canadian Cancer Trials Group Bulletins

Trial Management Group

CO.20 Closes to Accrual 4 Months Ahead of Projected!

CO.20 Trial Closes to Accrual 4 Months Ahead of Projected!

Despite the early restriction on stellar accrual from our Australasian colleagues, on 10 February 2011, CO.20 (A Phase III Randomized Study of Brivanib Alaninate [BMS-582664] in Combination with Cetuximab [Erbitux] Versus Placebo in Combination with Cetuximab in Patients With K-Ras Wild Type Tumours Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma) reached its target sample size of 750 patients -- 4 months ahead of initial projections!

Building on our history of success with the CO.17 trial in this patient population, over a period of just 34 months, 416 patients from Australasia (55%) and 334 patients from Canada (45%) were randomized to receive either brivanib alaninate (BMS-582664) or placebo in combination with cetuximab.

We extend our congratulations and heartfelt appreciation to investigators, CRAs and pharmacists at participating centres in Canada, Australia and New Zealand, and to the AGITG central office staff for their support and successful accrual to this important study.

Equally exciting is that CO.20 is also approaching the target number of events for final analysis. Expect to hear from us soon as we call for, review, query and clean data in anticipation of the final analysis.

The CO.20 Trial Team